Sanofi to acquire Amunix Pharmaceuticals in a $1.225bn deal
PARIS, FRANCE: Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals Inc, an immune-oncology company. Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology. Under the terms of the agreement, Sanofi will acquire Amunix Pharmaceuticals for…